Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

First patient enrolled in phase II study of MABp1 in atopic dermatitis

May 23, 2018

First-in-human study shows promise of SYNT-001 in pemphigus

May 22, 2018

FDA awards rare pediatric disease designation to CCP-020

May 17, 2018

Pivotal study of Dupixent in moderate to severe atopic dermatitis in adolescents meets key endpoints

May 16, 2018

First patient dosed in the phase I/II trial of KB-103

May 11, 2018

FDA approves IND for female hair loss trial of Histogen's HSC-660

May 7, 2018

Lilly initiates phase III study of mirikizumab in moderate to severe plaque psoriasis

May 7, 2018

Azitra raises new financing to advance pipeline

May 4, 2018

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

May 3, 2018

Exicure reports phase I data on AST-005 in plaque psoriasis

May 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026